Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917).
Nakayama T, Yoshinami T, Yasojima H, Kittaka N, Takahashi M, Ohtani S, Kim SJ, Kurakami H, Yamamoto N, Yamada T, Takata T, Masuda N. Nakayama T, et al. Among authors: ohtani s. BMC Cancer. 2021 Jul 9;21(1):795. doi: 10.1186/s12885-021-08504-1. BMC Cancer. 2021. PMID: 34238257 Free PMC article.
Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
Ohtani S, Nakayama T, Yoshinami T, Watanabe KI, Hara F, Sagara Y, Kawaguchi H, Higaki K, Matsunami N, Hasegawa Y, Takahashi M, Mizutani M, Morimoto T, Sato M, Itoh M, Morita S, Masuda N. Ohtani S, et al. Breast Cancer. 2018 Jul;25(4):438-446. doi: 10.1007/s12282-018-0843-y. Epub 2018 Feb 12. Breast Cancer. 2018. PMID: 29435730 Free PMC article. Clinical Trial.
The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
Takahashi M, Ohtani S, Nagai SE, Takashima S, Yamaguchi M, Tsuneizumi M, Komoike Y, Osako T, Ito Y, Ikeda M, Ishida K, Nakayama T, Takashima T, Asakawa T, Matsumoto S, Shimizu D, Masuda N. Takahashi M, et al. Among authors: ohtani s. Breast Cancer Res Treat. 2021 Jan;185(1):125-134. doi: 10.1007/s10549-020-05921-x. Epub 2020 Sep 13. Breast Cancer Res Treat. 2021. PMID: 32920732 Free PMC article. Clinical Trial.
Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
Iwasa T, Tsurutani J, Watanabe S, Kato R, Mizuno Y, Kojima Y, Takashima T, Matsunami N, Morimoto T, Yamamura J, Ohtani S, Tanabe Y, Yoshinami T, Takano T, Komoike Y, Nakagawa K. Iwasa T, et al. Among authors: ohtani s. BMC Cancer. 2019 Oct 16;19(1):962. doi: 10.1186/s12885-019-6200-5. BMC Cancer. 2019. PMID: 31619197 Free PMC article. Clinical Trial.
Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Kawaguchi H, et al. Among authors: ohtani s. Breast Cancer. 2020 May;27(3):389-398. doi: 10.1007/s12282-019-01029-3. Epub 2019 Dec 6. Breast Cancer. 2020. PMID: 31811519 Free PMC article.
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K, Yasojima H, Kasai H, Takasuka T, Sakurai T, Kataoka TR, Morita S, Ohno S, Toi M. Masuda N, et al. Among authors: ohtani s. Breast Cancer Res Treat. 2020 Feb;180(1):135-146. doi: 10.1007/s10549-020-05524-6. Epub 2020 Jan 17. Breast Cancer Res Treat. 2020. PMID: 31953696 Free PMC article.
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
Yamashiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Kuroi K, Takano T, Yasuno S, Morita S, Ohno S, Toi M; JBCRG-C01 Collaborative Group. Yamashiro H, et al. Among authors: ohtani s. Breast Cancer. 2020 Jul;27(4):631-641. doi: 10.1007/s12282-020-01057-4. Epub 2020 Feb 14. Breast Cancer. 2020. PMID: 32060785 Free PMC article.
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Ishiguro H, Masuda N, Sato N, Higaki K, Morimoto T, Yanagita Y, Mizutani M, Ohtani S, Kaneko K, Fujisawa T, Takahashi M, Kadoya T, Matsunami N, Yamamoto Y, Ohno S, Takano T, Morita S, Tanaka-Mizuno S, Toi M. Ishiguro H, et al. Among authors: ohtani s. Breast Cancer Res Treat. 2020 Apr;180(3):715-724. doi: 10.1007/s10549-020-05590-w. Epub 2020 Mar 13. Breast Cancer Res Treat. 2020. PMID: 32170634 Free PMC article. Clinical Trial.
471 results